Hirsch FR. An Update on the BLUEPRINT and Related Projects. 18th World Conference on Lung Cancer (WCLC) 2017, abstract MS 18.02.
FDA keurt pembrolizumab goed voor adjuvante behandeling stadium IIB/IIC-melanoom
dec 2021 | Dermato-oncologie, Immuuntherapie